Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MYO vs CDRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDRE Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

CDRE Overall Winner 6-Pillar Tally: MYO 1 – 5 CDRE Matrix Metrics: MYO 1 – 9 CDRE

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas CDRE carries 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin).

  • Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both MYO (40.1/100 SELL) and CDRE (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile CDRE trades in a Neutral technical trend (SURGE options phase, RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYO vs CDRE
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32
CDRE NYSE Head-to-Head Winner
Cadre Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$29.45
-3.63% 1D
Market Cap $1.3B
TTM Revenue $733M
Forward P/E 18.5x
Beta / 30D Vol 0.87β · 42% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.7 · SMA20: $31.80 · SMA50: $28.53

6-Pillar Scorecard Institutional Category Breakdown (MYO 1 – 5 CDRE)

Columns: Metric · MYO · CDRE
1. Valuation Multiples CDRE
Forward P/E N/M 18.5x
Trailing P/E N/M 33.6x
PEG Ratio N/M N/M
EV / Revenue 0.9x 2.2x
2. Growth & Scale CDRE
Revenue Growth (YoY) +22.2% +30.2%
Earnings Growth (YoY) +0.0% +37.5%
TTM Revenue (USD) $46M $733M
Market Cap $33.7M $1.3B
3. Profitability & Quality CDRE
Gross Margin 70.1% 42.8%
Operating Margin -21.8% 12.5%
Net Profit Margin -33.1% 5.6%
Return on Equity (ROE) -173.5% 11.6%
4. Balance Sheet & Cash Flow CDRE
Cash Generation (TTM) -$9.1M $76M
Cash Flow Margin -20.0% 10.4%
Net Cash / Leverage $8.9M Net Debt (3.44x D/E) $330M Net Debt (1.08x D/E)
Dividend Yield None (0.00%) 1.24%
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 266.0% (81st %ile) 47.3% (2nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat CDRE
OpEx & R&D Intensity N/A 30.3% of Rev ($222M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Aerospace & Defense Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYO (1) vs CDRE (9)
Institutional Metric MYO CDRE Criterion Row Edge
Market Capitalization
Scale
$33.7M $1.3B Larger Scale CDRE
Trailing P/E Ratio
Valuation
N/M 33.6x Lower Multiple CDRE
Forward P/E Ratio
Valuation
N/M 18.5x Lower Multiple CDRE
Revenue Growth (YoY)
Growth
+22.2% +30.2% Higher Growth CDRE
Operating Margin (TTM)
Profitability
-21.8% 12.5% Higher Margin CDRE
Net Profit Margin
Profitability
-33.1% 5.6% Higher Margin CDRE
Return on Equity (ROE)
Capital Efficiency
-173.5% 11.6% Higher ROE CDRE
52-Week Range Position
Momentum
16% ($1–$2) 22% ($24–$49) Stronger Trend CDRE
Beta / 30D Volatility
Risk Regime
2.22β · 107% Vol 0.87β · 42% Vol Lower Realized Risk CDRE
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 39.6 / 100 (SELL) Higher Composite MYO
Trailing 12M Revenue (USD)
Operating Scale
$46M $733M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.1% 42.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($8.9M Net Debt (3.44x D/E)) $76M ($330M Net Debt (1.08x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDRE +33.49 pp
MYO: -33.52% · CDRE: -0.03%
3M Horizon CDRE +30.68 pp
MYO: -41.65% · CDRE: -10.97%
6M Horizon CDRE +19.18 pp
MYO: -22.02% · CDRE: -2.84%
1Y Horizon MYO +38.68 pp
MYO: +12.3% · CDRE: -26.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MYO Revenue CDRE Revenue MYO Op. Margin CDRE Op. Margin Margin Leader
FY2018 $0M N/A -430.8% N/A MYO
FY2019 $0M N/A -281.3% N/A MYO
FY2020 $10M $400M -138.5% 12.3% CDRE
FY2021 $10M $430M -74.1% 12.1% CDRE
FY2022 $20M $460M -68.6% 3.7% CDRE
FY2023 $20M $480M -42.8% 11.7% CDRE
FY2024 $30M $570M -19.1% 11.8% CDRE
FY2025 $40M $610M -35.2% 11.0% CDRE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDRE SURGE
9d in phase · OBV DISTRIBUTION
Current IV 47.3%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CDRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDRE Moat Profile Cyclical / Execution-Driven Positioning
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $1.3B market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 30.3% of Rev ($222M)
90D Engineering Disclosures 0 Published

Investor FAQ MYO vs CDRE Key Questions & Quantitative Answers

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas CDRE carries 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin). Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both MYO (40.1/100 SELL) and CDRE (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile CDRE trades in a Neutral technical trend (SURGE options phase, RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDRE leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with CDRE at +30.2% YoY revenue growth and +37.5% YoY earnings growth on $733M TTM revenue (42.8% gross margin, 12.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while CDRE shifted +52.5%. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus 30.3% of Rev ($222M) (0 disclosures) for CDRE.

CDRE screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas CDRE trades at 18.5x Forward P/E, 33.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (10.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus CDRE (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, CDRE carries 47.3% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.87β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.